About REMED
REMED is a publicly listed company based in Daejeon (South Korea) founded in 2003. Products for the treatment of brain disorders and pain management. The company has 104 employees. REMED offers products and services including Electronic Medicine Solutions and Differentiated Medical Platforms. Its focus areas include Life Sciences, Neurology, Medical Devices and Therapeutic Devices. Its legal entity in India is μ£Όμνμ¬ λ¦¬λ©λ (U99999MH1977PLC010754).
Company details
REMED develops products for the treatment of brain disorders (depression, anxiety, stroke and Parkins), and pain management. Products developed by the company include Transcranial Magnetic Stimulation Therapy device, Electromagnetic Stimulation device, Extracorporeal Shockwave Therapy, Electrosurgical Unit, Patient Monitor, Fetal Monitor, and ECG device.
- Annual Revenue$16.96 M (USD)-4.11as on Dec 31, 2025
- Net Profit$364.35 K (USD)-92.66as on Dec 31, 2025
- EBITDA$1.48 M (USD)-10.7as on Dec 31, 2025
- Employee Count104
Associated legal entities of REMED
REMED operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | View details |
Products & Services of REMED
REMED offers a comprehensive portfolio of products and services, including Electronic Medicine Solutions and Differentiated Medical Platforms.
Tools for non-invasive brain disease treatment and procedures
Platforms supporting psychiatry and veterinary innovations
IPO & Listings of REMED
REMED is a publicly listed company on the KRX with ticker symbol 302550 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date06 Dec 2019
- Listed onKRX: 302550
- Listed entityREMED Co., Ltd.
- Exchange sectorHealth technology
- ISINKR7302550009
- Share price2,415.00 KRW (-8.52% on the day) · 2026-10-14
- Market capitalisation79,926,034,241.00 KRW
- Price to earnings49.4
- EPS (diluted, trailing year)48.93 KRW
- Volume (last session)899,936
Financials of REMED
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 24.50B KRW | 526.2M KRW | 2.14B KRW |
| 2024 | 25.55B KRW | 7.17B KRW | 2.40B KRW |
| 2023 | 18.54B KRW | 797.2M KRW | -1.91B KRW |
| 2022 | 21.36B KRW | 4.00B KRW | 2.42B KRW |
| 2021 | 20.20B KRW | 752.3M KRW | 1.68B KRW |
Balance sheet, profit and loss, cash flow and ratios of , are on its company page.
Detailed financial statements for REMED
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of REMED
The website of REMED (remed.kr) receives about 4.1K visits a month.
- Monthly visits4.1K
▼ 10.5% vs previous month
Websites whose visitors overlap most with REMED. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
knpa.or.kr | knpa.or.kr | 100% | #5,836,149 | β |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Remed
Complete news archive for REMED
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about REMED
REMED was founded in 2003.
REMED is headquartered in Daejeon, South Korea.
REMED has 104 employees.
Annual revenue of REMED is $16.96M as on Dec 31, 2025.
REMED develops products for the treatment of brain disorders (depression, anxiety, stroke and Parkins), and pain management. Products developed by the company include Transcranial Magnetic Stimulation Therapy device, Electromagnetic Stimulation device, Extracorporeal Shockwave Therapy, Electrosurgical Unit, Patient Monitor, Fetal Monitor, and ECG device.
REMED offers Electronic Medicine Solutions and Differentiated Medical Platforms.
Yes, REMED is publicly traded on KRX under the ticker symbol 302550.
REMED operates through ,.